Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to thromboembolism: pulmonary thromboembolism


The blocking of a blood vessel by a blood clot dislodged from its site of origin.

throm′bo·em·bol′ic (-ĕm-bŏl′ĭk) adj.


(Pathology) pathol the obstruction of a blood vessel by a thrombus that has become detached from its original site


(ˌθrɒm boʊˈɛm bəˌlɪz əm)

the blockage of a blood vessel by a thrombus carried through the bloodstream.
throm`bo•em•bol′ic (-ɛmˈbɒl ɪk) adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.thromboembolism - occlusion of a blood vessel by an embolus that has broken away from a thrombus
occlusion - closure or blockage (as of a blood vessel)


n (pl -li) tromboembolia
References in periodicals archive ?
Objective: To determine the frequency of prothrombin gene mutation in venous thromboembolism in our population.
The new dosage is intended to decrease the continued risk for recurrent venous thromboembolism (VTE) after around six months of initial anticoagulation therapy.
In a Swedish study, published in the American Heart Association journal Circulation: Cardiovascular Genetics, the risk of venous thromboembolism for men shorter than five feet three inches dropped 65 percent compared to men taller than 6 feet two inches.
Venous thrombosis, comprising of deep venous thrombosis and pulmonary thromboembolism constitute a significant cause of morbidity and mortality that is potentially preventable.
PE and deep vein thrombosis (DVT), as two different forms of venous thromboembolism (VTE) on patients, cannot be separated apart in the management.
The report forecasts the Venous Thromboembolism market containing deep vein thrombosis and pulmonary embolism, to grow at a compound annual growth rate (CAGR) of 2.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are together referred to as venous thromboembolism (VTE).
ROUTINE THROMBOEMBOLISM RISK assessment, and use of both pharmacologic and mechanical thromboprophylaxis, is an important part of obstetrics care, according to new recommendations from the National Partnership for Maternal Safety.
Voluntary ex ante transparency notice: provision of equipment and supply of consumables necessary for the prevention of venous thromboembolism in the regional hospital of orleans.
Venous thromboembolism may affect 1 in 1000 individuals per year (1), carries a 1-month fatality rate of 3% for deep venous thrombosis and of 31% for pulmonary embolism (2), and has traditionally been considered a time-limited acute disease treated with 3-12 months of anticoagulant medication (3).
In our analysis, based on 21 vaccine exposed cases, there was no significant association with venous thromboembolism within 90 days after exposure to [quadrivalent] HPV vaccine.
KEY WORDS: Factor V Leiden, Venous thromboembolism, Deep vein thrombosis.